CURRENT
ISSUE
1530
September 25, 2017
Alzheimer's disease (AD) is the most common cause
of dementia, but cognitive loss is also associated with
other neurological conditions such as Parkinson's
disease, dementia with Lewy bodies, vascular dementia,
and frontotemporal dementia.... Continue reading
More from Issue 1530
Previous Issue: 1529 September 11, 2017
- Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
- Prasterone (Intrarosa) for Dyspareunia
- Safinamide (Xadago) for Parkinson's Disease
- Deflazacort (Emflaza) for Duchenne Muscular Dystrophy
- Correction: Drugs for Helicobacter pylori Infection
Coming Soon
Influenza Vaccine for 2017-2018
Two New Combinations for Chronic HCV Infection - Vosevi and Mavyret
In Brief: Pancreatic Enzyme Replacement Products
Drugs for Respiratory Tract Infections
Subscribe
Reader Testimonials
Tweets
FROM
ISSUE
1530
The FDA has approved the interleukin-6 (IL-6) receptor antagonist tocilizumab (Actemra – Genentech) for subcutaneous (SC) treatment of giant cell arteritis in adults. It is the first drug to be approved in the US for this indication. Tocilizumab is also approved for treatment of rheumatoid arthritis, polyarticular or systemic juvenile idiopathic arthritis, and cytokine release syndrome.1
THE DISEASE — Giant cell arteritis is a systemic large vessel vasculitis that usually occurs in adults >50 years old. It ...
